Retatrutide

Sign up for news and updates

Past or current medical history (Check those questions to which you answer yes leave the others blank)
Heart DiseaseDisease of the arteriesHigh blood cholesterolAnemia or other bloos disordersStrokeThyroid cancerParathyroid or Adrenal gland problemsDiabetes or abnormal blood sugarDeep Vein Thrombosis (DVT)Gallstones or gallbladder disease HTNKidney problems including CKDBreathing problems such as asthmaPancreas/ Digestion problems Stomach/ GastricUlcerLiver ProblemsNeurological IssuesEating DisorderDepressionAnxietySubstance Abuse

I confirm that I accept the extra blood tests with further monitoring as above if required with an additional cost as specified in the Patient price list.

COMMUNICATION: Every client is an individual, and it is not possible to determine in advance how your system will react to the treatment. It is sometimes necessary to adjust your program as we proceed. It is your responsibility to do your part by following healthy dietary guidelines, exercise your body and make necessary behavioral modifications.

• 1. Alternatives to Retatrutide therapy are surgical procedures, oral medical treatments (including Orlistat) and / or dietary and lifestyle changes alone.

• 2. Several weeks to months of treatment may be required depending on your individual response.

• 3. If a missed dose is more than 5 days late, the missed dose should not be taken, and the next dose should be taken at the normal time.

• 4. It is essential to combine eating, exercise and behavioral modifications with Retatrutide.

• 5. Retatrutide should not be used in combination with another GLP-1 receptor agonist, insulin or insulin secretagogues (such as sulfonylureas) due to the risk of hypoglycaemia.

• 6. Upon initiation of Retatrutide treatment in patients on warfarin or other coumarin derivatives more frequent monitoring of International Normalized Ratio (INR) is recommended.

• 7. Retatrutide causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor for potential consequences of delayed absorption of oral medications concomitantly administered with Retatrutide

• 8. There are several special warnings and precautions for use of Retatrutide including warnings on pancreatitis, cholelithiasis and cholecystitis, thyroid disease, heart rate, dehydration and hypoglycaemia in people with type 2 diabetes.

• 9. Thyroid adverse events, such as goiter have been reported in particular in patients with pre-existing thyroid disease. Retatrutide should therefore be used with caution in patients with thyroid disease.

• 10. A higher rate of cholelithiasis and cholecystitis (gallstone and gallbladder disease) has been observed in patients treated with Retatrutide. Cholelithiasis and cholecystitis may lead to hospitalization and cholecystectomy (surgery to remove the gallbladder Patients should be aware of the characteristic symptoms of cholelithiasis and cholecystitis.

• 11. Signs and symptoms of dehydration, including renal impairment and acute renal failure, have been reported in patients treated with Retatrutide. Patients treated with Retatrutide should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion. Patients should also be aware of the symptoms of increased heart rate.

• 12. Acute pancreatitis has been observed with the use of Retatrutide. Patients and their carers should be told how to recognise signs and symptoms of acute pancreatitis and advised to seek immediate medical attention if symptoms develop. If pancreatitis is suspected, Retatrutide should be discontinued; if acute pancreatitis is confirmed, Retatrutide should not be restarted.

• 13. Retatrutide may cause dose-dependent and Treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Retatrutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (cancer, MTC), in humans, as the human relevance of Retatrutide-induced rodent thyroid C-cell tumors has not been determined. Patients should be aware of symptoms of thyroid tumors (such as a mass in the neck, difficulty swallowing, difficulty breathing or shortness of breath, persistent hoarseness

The most common Saxenda side effects are:

• • Nausea

• • Constipation

• • Decreased appetite

• • Dizziness

• • Hypoglycemia

• • Vomiting

• • Dyspepsia

• • Abdominal pain

• • Diarrhea

• • Headache

• • Fatigue

• • Increased lipase

Nausea is the most common side effect when first starting Sexenda®, but decreases over time for most people as their body gets used to the medicine. The dosing schedule is designed to reduce the likelihood of gastrointestinal symptoms. Tell your health care professional if you have any side effect that bothers you or that does not go away.

Risks of Retatrutide treatment include but are not limited to:

• a. Common or very common, reported in 5%: Dysgeusia (altered sense of taste), dry mouth, insomnia, asthenia; burping; constipation; diarrhea; dizziness; dry mouth; gallbladder disorders; gastrointestinal discomfort; gastrointestinal disorders; insomnia; nausea; vomiting, hypoglycaemia, dyspepsia, gastritis, gastro-oesophageal reflux disease, flatulence, eructation, upper abdomen pain, abdomen distension, cholelithiasis, injection site reactions, fatigue, increased lipase and increased amylase.

• b. Uncommon: Malaise; pancreatitis; tachycardia; urticaria

• c. Rare: Renal impairment, allergic reaction, anaphylaxis

Do not take Retatrutide if any of the below contraindications apply to you:

• a. Aged under 18 or above 75

• b. Severe renal/kidney impairment (with eGFR of 15 or below) or a history of renal disease

• c. Severe hepatic/liver impairment

• d. Personal or family history of medullary thyroid cancer (MTC)

• e. Hypersensitivity to Retatrutide or to any of the excipients: disodium phosphate dihydrate, propylene glycol, phenol and water for injection

• f. Concurrent treatment with any other products for weight management

• g. Weight problems related to endocrinological or eating disorders

• h. Concurrent insulin or sulfonylurea

• i. Patients on warfarin (more frequent INR monitoring required)

• j. Concurrent use of any medicinal products may cause weight gain

• k. Pregnancy, breastfeeding or trying to/planning to become pregnant. Congestive heart failure

• m. History of pancreatitis, gallbladder disease, inflammatory bowel disease, diabetic gastroparesis.

The below drugs interact with Retatrutide and treatment of Retatrutide should not be used concurrently. Drug interactions:

• • Alogliptin

• • Biphasic insulin aspart

• • Biphasic insulin lispro

• • Biphasic isophane insulin

• • Canagliflozin

• • Dapagliflozin

• • Dulaglutide

• • Empagliflozin

• • Exenatide

• • Glibenclamide

• • Gliclazide

• • Glimepiride

• • Glipizide

• • Any insulin including aspart, degludec, detemir, glargine, glulisine, lispro, isophane, zinc suspension

• • Nateglinide

• • Pioglitazone

• • Repaglinide Saxagliptin, Sitagliptin, Vildagliptin

• • Tolbutamide

I am aware that other unforeseeable complications could occur. I do not expect the clinic to anticipate and or explain all risk and possible complications. I rely on them to exercise judgment during the course of treatment. I understand the risks and benefits of the treatment and have had the opportunity to have all of my questions answered.

I understand that I have the right to consent to or refuse any proposed treatment at any time prior to its performance. At any stage during the treatment, I have the right to request that the procedure is terminated, however accept that I will not be reimbursed once supply has commenced.

I declare that the info I’ve provided is accurate & complete

I agree to all the terms of this contract